<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745105</url>
  </required_header>
  <id_info>
    <org_study_id>CEBD-CU-2018-11-01</org_study_id>
    <nct_id>NCT03745105</nct_id>
  </id_info>
  <brief_title>Comparative Evaluation of the Effect of Prophylactic Intraligamentary Injection of Dexamethasone and Piroxicam on Postoperative Pain in Teeth With Symptomatic Irreversible Pulpitis</brief_title>
  <official_title>Comparative Evaluation of the Effect of a Prophylactic Intraligamentary Injection of Dexamethasone and Piroxicam on Postoperative Pain in Teeth With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study is conducted to assess and compare the efficacy of local intraligamentary injection
      of glucocorticoids(dexamethasone) and NSAID(piroxicam) on reduction of postoperative pain in
      patients with symptomatic irreversible pulpitis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 25, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post operative pain assessed with the Numerical Rating Pain Scale</measure>
    <time_frame>up to 48 hours after root canal treatment (At 4,6,12,24 and 48 hours after root canal treatment ).</time_frame>
    <description>Intensity of pain after endodontic treatment is recorded by the patient using a numerical rating scale(where 0= no pain ,1-3 =mild pain ,4-6= moderate pain and 7-9= severe pain )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of analgesics taken by the patient</measure>
    <time_frame>Until 48 hours after endodontic treatment.</time_frame>
    <description>Number of analgesic tablets taken by the patient after endodontic treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pretreatment intraligamentary injection of 0.4 mL of 8 mg/2 mL dexamethasone (Dexamethasone, AMRIYA pharmaceutical, Egypt)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>piroxicam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pretreatment intraligamentary injection of 0.4 mL of 20 mg mL-1 piroxicam (Feldene, Pfizer, Egypt)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mepivacaine HCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pretreatment Intraligamentary injection of 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml (Mepecaine - L, Alexandria Co.-Egypt)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone sodium phosphate</intervention_name>
    <description>prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.</description>
    <arm_group_label>dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piroxicam Injectable Solution</intervention_name>
    <description>prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam</description>
    <arm_group_label>piroxicam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepivacaine HCL</intervention_name>
    <description>prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml</description>
    <arm_group_label>Mepivacaine HCL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Systemically healthy patient (ASA I or II).

          2. Mandibular Posterior teeth with:

               -  Preoperative sharp pain.

               -  Absence of widening in the periodontal ligament (PDL).

               -  Vital response of pulp tissue to cold pulp tester (ethyl chloride spray).

        Exclusion Criteria:

          1. Patients allergic to anesthetics, piroxicam (any other NSAIDs) or dexamethasone (other
             corticosteroids).

          2. Pregnant or nursing females.

          3. Patients having significant systemic disorder (ASA III or IV).

          4. Hemostatic disorders or anti-coagulant therapy during the last month.

          5. Consumption of opioid or non-opioid analgesics or corticosteroids during the last 12
             hrs before treatment.

          6. Retreatment cases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Safwa Es. Abd Elglil, B.D.S. (Cairo University)</last_name>
    <phone>01001259618</phone>
    <phone_ext>002</phone_ext>
    <email>safwaessam91@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Mehrvarzfar P, Esnashari E, Salmanzadeh R, Fazlyab M, Fazlyab M. Effect of Dexamethasone Intraligamentary Injection on Post-Endodontic Pain in Patients with Symptomatic Irreversible Pulpitis: A Randomized Controlled Clinical Trial. Iran Endod J. 2016 Fall;11(4):261-266.</citation>
    <PMID>27790253</PMID>
  </reference>
  <reference>
    <citation>Atbaei A, Mortazavi N. Prophylactic intraligamentary injection of piroxicam (feldene) for the management of post-endodontic pain in molar teeth with irreversible pulpitis. Aust Endod J. 2012 Apr;38(1):31-5. doi: 10.1111/j.1747-4477.2010.00274.x. Epub 2010 Oct 24.</citation>
    <PMID>22432824</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>November 20, 2018</last_update_submitted>
  <last_update_submitted_qc>November 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Safwa Essam Mohammed Ahmed Abd el-glil</investigator_full_name>
    <investigator_title>resident at faculty of dentistry cairo university</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulpitis</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Piroxicam</mesh_term>
    <mesh_term>Mepivacaine</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

